There was no significant difference in survival outcomes with trabectedin or physician’s choice of chemotherapy.
The prevalence of screening for colorectal cancer remained stable.
Investigator analysis showed that PFS was improved in the intent-to-treat population with rucaparib, as well as in the HRD population.
Combining relacorilant with nab-paclitaxel improved overall survival in a subset of patients with recurrent, platinum-resistant ovarian cancer.
The malignancy rate was less than 1% for classic lesions and 32% for nonclassic lesions with blood flow.
To reduce waste and cut costs, researchers recommend making ICG available in a 10 mg vial.
Non-Hispanic Black heterosexuals were the group most likely to undergo screening.
Quality of life outcomes were reported favorably for trials that showed no improvement in quality of life.
The greatest benefit was observed when chemotherapy was combined with external beam radiation therapy and vaginal brachytherapy.
Barbara Goff, MD, discusses ovarian cancer and how recognizing symptoms can lead to early detection and reduce misdiagnosis.
Fasting insulin, bioavailable testosterone, and sex hormone binding globulin were found to play a role in the relationship between BMI and endometrial cancer risk.
Researchers identified associations between pathogenic variants in BRCA1/2 and 7 cancers.
Fuzuloparib maintenance significantly delayed the time to disease progression and time to subsequent chemotherapy.
This weekly series highlights eponyms in oncology. This week, we explore the history and namesake of HeLa cells.
The median duration of response was significantly longer with rucaparib than with standard chemotherapy.
Patients who have mismatch repair proficiency in the primary setting may have mismatch repair deficiency at recurrence.
Despite the lack of improvement in the overall cohort, olaparib monotherapy and olaparib-cediranib did exhibit activity in a subset of patients with a germline BRCA mutation.
Researchers discovered actionable germline genetic variants in 20% of patients who did not meet genetic testing criteria according to prior guidelines.
Selinexor was associated with a 30% decrease in the risk of progression or death.
At the start of the pandemic, there was an immediate 34.3% decline in the estimated mean cancer incidence volume.